Dr. Da Silva has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers. She has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human samples.
Dr. Da Silva is the course director for a newly developed undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies that started in Spring 2015.
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed
Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin Immunol. 2015 Dec; 161(2):197-208. . View in PubMed
Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype Virology. 2014 Mar; 452-453:279-86. . View in PubMed